Scholarlink

Background <p>Systemic sclerosis (SSc) is a rare connective tissue disease associated with rapidly evolving interstitial lung disease (ILD), driving its mortality. Specific imaging-based biomarkers associated with the evolution of lung disease are needed to help predict and quantify ILD.</p> Methods <p>We evaluated the potential of an automated ILD quantification system (icolung<sup>®</sup>) from chest CT scans, to help in quantification and prediction of ILD progression in SSc-ILD. We used a retrospective cohort of 75 SSc-ILD patients to evaluate the potential of the AI-based quantification tool and to correlate image-based quantification with pulmonary function tests and their evolution over time.</p> Results <p>We evaluated a group of 75 patients suffering from SSc-ILD, either limited or diffuse, of whom 30 presented progressive pulmonary fibrosis (PPF). The patients presenting PPF exhibited more extensive lesions (in % of total lung volume (TLV)) based on image analysis than those without PPF: 3.93 (0.36–8.12)* vs. 0.59 (0.09–3.53) respectively, whereas pulmonary functional test showed a reduction in Force Vital Capacity (FVC)(pred%) in patients with PPF compared to the others : 77 ± 20% vs. 87 ± 19% (<i>p</i> &lt; 0.05). Modifications of FVC and diffusing capacity of the lungs for carbon monoxide (DLCO) over time were correlated with longitudinal radiological ILD modifications (<i>r</i>=-0.40, <i>p</i> &lt; 0.01; <i>r</i>=-0.40, <i>p</i> &lt; 0.01 respectively).</p> Conclusion <p>AI-based automatic quantification of lesions from chest-CT images in SSc-ILD is correlated with physiological parameters and can help in disease evaluation. Further clinical multicentric validation is necessary in order to confirm its potential in the prediction of patient’s outcome and in treatment management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Automated AI-based image analysis for quantification and prediction of interstitial lung disease in systemic sclerosis patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月24日

查看全文
  • Julien Guiot,
  • Monique Henket,
  • Fanny Gester,
  • Béatrice André,
  • Benoit Ernst,
  • Anne-Noelle Frix,
  • Dirk Smeets,
  • Simon Van Eyndhoven,
  • Katerina Antoniou,
  • Lennart Conemans,
  • Janine Gote-Schniering,
  • Hans Slabbynck,
  • Michael Kreuter,
  • Jacobo Sellares,
  • Ioannis Tomos,
  • Guang Yang,
  • Clio Ribbens,
  • Renaud Louis,
  • Vincent Cottin,
  • Sara Tomassetti,
  • Vanessa Smith,
  • Simon L. F. Walsh

摘要

Background

Systemic sclerosis (SSc) is a rare connective tissue disease associated with rapidly evolving interstitial lung disease (ILD), driving its mortality. Specific imaging-based biomarkers associated with the evolution of lung disease are needed to help predict and quantify ILD.

Methods

We evaluated the potential of an automated ILD quantification system (icolung®) from chest CT scans, to help in quantification and prediction of ILD progression in SSc-ILD. We used a retrospective cohort of 75 SSc-ILD patients to evaluate the potential of the AI-based quantification tool and to correlate image-based quantification with pulmonary function tests and their evolution over time.

Results

We evaluated a group of 75 patients suffering from SSc-ILD, either limited or diffuse, of whom 30 presented progressive pulmonary fibrosis (PPF). The patients presenting PPF exhibited more extensive lesions (in % of total lung volume (TLV)) based on image analysis than those without PPF: 3.93 (0.36–8.12)* vs. 0.59 (0.09–3.53) respectively, whereas pulmonary functional test showed a reduction in Force Vital Capacity (FVC)(pred%) in patients with PPF compared to the others : 77 ± 20% vs. 87 ± 19% (p < 0.05). Modifications of FVC and diffusing capacity of the lungs for carbon monoxide (DLCO) over time were correlated with longitudinal radiological ILD modifications (r=-0.40, p < 0.01; r=-0.40, p < 0.01 respectively).

Conclusion

AI-based automatic quantification of lesions from chest-CT images in SSc-ILD is correlated with physiological parameters and can help in disease evaluation. Further clinical multicentric validation is necessary in order to confirm its potential in the prediction of patient’s outcome and in treatment management.